Erteberel

Cat. No. :	HY-18295
M.Wt:	282.33
Formula:	C18H18O3
Purity:	>98 %
Solubility:	DMSO : ≥ 30 mg/mL

Introduction of 533884-09-2 :

Erteberel (LY500307) is a potent and selective estrogen receptor beta (ERβ) agonist with K_i and EC₅₀ of 1.54 nM and 3.61 nM, respectively. Erteberel has anti-tumor activities^[1][2]. IC50 & Target:Ki: 1.54 nM (ERβ)^[1]

EC50: 3.61 nM^[1]

In Vitro:Treatment with Erteberel (0.25-10 μM, 72 hours) significantly reduces the proliferation of GBM cells with no activity on normal astrocytes in vitro^[2].

Erteberel promotes apoptosis of GBM cells. Erteberel modulated several pathways related to apoptosis, cell cycle, and DNA damage response^[2].

Erteberel (0-1000 μM) sensitizes GBM cells to several FDA-approved chemotherapeutic drugs including cisplatin, lomustine and temozolomide^[2].

In Vivo:Erteberel (5?mg/Kg body weight/day, oral, 28 days) treatment significantly reduces tumor growth and promotes apoptosis of GBM tumors in an orthotopic model^[2].

Erteberel (5?mg/Kg body weight/day, oral, 40-50 days) treatment improves the overall survival of tumor-bearing mice in the GL26 syngeneic glioma model^[2].